Mycophenolic acid
Mycophenolic acid, inosine monophosphate dehydrogenase inhibitor
Written by Aaron CuhaReviewed Sep 2026
Also known as: Mycophenolate mofetil, MMF, CellCept, Myfortic, MPA
A transplant immunosuppressant tested on the logic that rapamycin's lifespan effect might come from immune suppression. It did not extend mouse lifespan in either sex, which argues that rapamycin works some other way.
Overview
Rapamycin is the most robust pharmacological lifespan extender known in mice, and it is also an immunosuppressant used to prevent transplant rejection. That raises an obvious question: is the lifespan effect a consequence of dampening the immune system, or of inhibiting mTOR?
Mycophenolic acid is a way to ask. It is a potent immunosuppressant that works nowhere near mTOR, blocking purine synthesis in lymphocytes specifically. If immune suppression were the active ingredient, it should reproduce at least part of rapamycin's effect.
In the Interventions Testing Program's 2024 cohort it did not increase lifespan in either sex. That is a useful negative, because it makes the immune-suppression explanation for rapamycin less likely and leaves mTOR inhibition standing.
Mechanism of action
A reversible inhibitor of inosine monophosphate dehydrogenase, the rate-limiting enzyme in de novo guanosine nucleotide synthesis. T and B lymphocytes depend on the de novo pathway because they lack an effective salvage pathway, so inhibiting it suppresses lymphocyte proliferation with relative selectivity. That selectivity is the basis of its transplant use and also the reason it is a clean probe: it suppresses immunity without touching the nutrient-sensing pathways rapamycin acts on.
Human evidence
A large approved-drug record in transplantation and autoimmune disease, with serious documented harms. No ageing endpoints.
- Standard of care in combination regimens for preventing solid organ transplant rejection.
- Widely used in lupus nephritis and other autoimmune conditions.
- Boxed warnings cover embryofetal toxicity, increased risk of lymphoma and other malignancies, and serious infection including progressive multifocal leukoencephalopathy.
- Gastrointestinal effects and marrow suppression are common and dose-limiting.
- No human study has examined lifespan, healthspan or any geroscience endpoint.
What this does not tell you: This drug exists to suppress immunity and its harms follow from that. The lifespan null tells you the drug does not extend life in mice; it does not exclude that some narrower immune intervention might. Nothing here supports any ageing use, and the malignancy and infection warnings make experimentation genuinely dangerous.
Reading the research record
The value of this null is what it rules out rather than what it shows. Rapamycin extends lifespan in mice more reliably than anything else in pharmacology, and it is an immunosuppressant, so the possibility that immune suppression is the mechanism has to be addressed. Testing a potent immunosuppressant that works through an entirely unrelated pathway is the right way to address it, and the answer was no lifespan extension.
That strengthens the mTOR explanation for rapamycin by elimination. It is an argument from a single null in one programme, so it constrains rather than settles the question.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Compounds are fed in the diet, both sexes are tested, cohorts are large enough to detect roughly a 10 percent lifespan change, and results are analysed by log-rank for median survival and by the Wang-Allison test for maximum lifespan. Its nulls are published alongside its positives. That combination of features does not exist anywhere else in ageing research, which is why a null here means considerably more than a null from a single laboratory.
The evidence, charted
Fig. 1 · evidence composition
0of 1 citation (0%) is in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2024.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Animal2024
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not
Interventions Testing Program. Mycophenolic acid did not increase lifespan significantly at the dose and method of administration tested, in either sex.
GeroScience
Frequently asked questions
Does suppressing the immune system extend lifespan?
Not on this evidence. A potent immunosuppressant acting through a pathway unrelated to mTOR produced no lifespan extension in either sex. That makes immune suppression a less likely explanation for rapamycin's lifespan effect and leaves mTOR inhibition as the better candidate.
Could I take this for longevity?
No, and this is among the strongest no answers here. It carries boxed warnings for embryofetal toxicity, malignancy and serious infection, and there is no ageing benefit at all on the other side of that ledger.
Why test a transplant drug for ageing?
To separate two possible explanations for rapamycin's effect. If immune suppression were doing the work, an unrelated immunosuppressant should have shown something. It did not, which is how a well-chosen null advances a field.